Proteasome pathway, Rho-signaling cascade, NF-κB (nuclear factor kappa light-chain enhancer of activated B cells) signaling pathway, and related cross-talk were proven by Downward and coworkers to be essential for KRAS-mutated NSCLC viability. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.